glutamic acid has been researched along with Autosomal Dominant Juvenile Parkinson Disease in 96 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 52 (54.17) | 29.6817 |
| 2010's | 36 (37.50) | 24.3611 |
| 2020's | 8 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Mannoury-la-Cour, C; Mantas, I; Millan, MJ; Svenningsson, P; Yang, Y; Zhang, X | 1 |
| Lee, S; Pare, JF; Smith, Y; Villalba, RM | 1 |
| Kalinina, TS; Kiselev, AV; Sergienko, VI; Stovbun, IS; Vedenkin, AS | 1 |
| Galvan, A; Smith, Y; Swain, AJ; Wichmann, T | 1 |
| Brugnoli, A; Caccia, C; Keywood, C; Melloni, E; Morari, M; Novello, S; Padoani, G; Pisanò, CA; Vailati, S | 1 |
| Bastioli, G; Caccia, C; Calabresi, P; Cardinale, A; Ghiglieri, V; Keywood, C; Mazzocchetti, P; Melloni, E; Mosci, P; Padoani, G; Picconi, B; Sciaccaluga, M; Tozzi, A; Vailati, S | 1 |
| Brugnoli, A; Morari, M; Pisanò, CA | 1 |
| Kucheryanu, VG; Vetrile, LA; Voronina, NA; Zakharova, IA | 1 |
| Aoto, J; Boxer, EE; Cai, Y; Ford, CP; Nielsen, BE | 1 |
| Gao, S; Guo, Y; Li, R; Li, W; Liu, J; Lyu, S; Tang, G; Yang, J; Zhang, L | 1 |
| Akiyama, JI; Aono, H; Choudhury, ME; Fujita, K; Higaki, H; Kigami, Y; Kubo, M; Miyanishi, K; Nishikawa, N; Nomoto, M; Takahashi, H; Tanaka, J; Yano, H | 1 |
| Du, CX; Guo, Y; Li, LB; Liu, J; Sun, YN; Wang, Y; Yao, L | 1 |
| Bastioli, G; Calabresi, P; Costa, C; Di Filippo, M; Durante, V; Mancini, A; Mazzocchetti, P; Mechelli, A; Morari, M; Novello, S; Tozzi, A | 1 |
| Ariza, D; Crestani, CC; Cruz Lucchetti, BF; de Jager, L; Martins, AB; Martins-Pinge, MC; Pinge-Filho, P; Rodrigues, AT; Turossi Amorim, ED; Uchoa, ET | 1 |
| Ai, Y; Andersen, A; Fan, XT; Gerhardt, GA; Hardy, P; Ling, F; Quintero, JE; Zhang, Z; Zhao, F | 1 |
| Czarnecka, A; Lorenc-Koci, E | 1 |
| Chergui, K; Feng, ZJ; Zhang, X | 1 |
| Ampe, B; Aourz, N; Bentea, E; De Deurwaerdère, P; El Arfani, A; Massie, A; Michotte, Y; Sarre, S; Smolders, I; Van Eeckhaut, A | 1 |
| Dale, E; Doller, D; Gubellini, P; Kerkerian-Le Goff, L; Melon, C | 1 |
| Deng, X; Fang, X; Li, J; Li, S; Lu, Y; Xu, R; Zhang, J; Zhou, Y | 1 |
| Atherton, JF; Bevan, MD; Chu, HY; Surmeier, DJ; Wokosin, D | 1 |
| Gittis, AH; Mastro, KJ | 1 |
| Papa, SM; Wichmann, T | 1 |
| Aschner, M; Bowman, AB; Kwakye, GF; Mukhopadhyay, S; Paoliello, MM | 1 |
| Albertini, G; Bentea, E; Demuyser, T; El Arfani, A; Massie, A; Smolders, I; Van Eeckhaut, A | 1 |
| Alvarsson, A; Kadkhodaei, B; Millan, MJ; Perlmann, T; Schintu, N; Stan, TL; Svenningsson, P; Zhang, X | 1 |
| Aytan, N; Brownell, AL; Choi, JK; Dedeoglu, A; Jenkins, BG; Kil, KE; Kuruppu, D; Poutiainen, P; Zhang, Z; Zhu, A | 1 |
| Bezard, E; Cenci, MA; Conn, PJ; Fieblinger, T; Francardo, V; Greengard, P; Ko, WK; Li, Q; Lindsley, CW; Neubig, RR; Plotkin, JL; Shen, W; Surmeier, DJ; Wess, J; Xie, Z | 1 |
| McCreary, AC; Newman-Tancredi, A; Varney, MA | 1 |
| Czarnecka, A; Konieczny, J; Lenda, T | 1 |
| Deng, JH; Gong, XL; Jia, J; Jia, YJ; Sun, ZL; Wang, XM; Yang, J; Yu, Y; Zhang, WZ | 1 |
| Antipova, TA; Gudasheva, TA; Koliasnikova, KN; Seredenin, SB | 1 |
| Bishop, C; Conti, MM; George, JA; Goldenberg, AA; Lindenbach, D; Melikhov-Sosin, M; Nuss, EE; Ostock, CY | 1 |
| Bäckman, CM; Boger, HA; Farrand, AQ; Gregory, RA; Helke, KL | 1 |
| Cao, X; Chen, G; Han, C; Ma, K; Nie, S; Papa, SM; Wang, T; Xiong, N; Xu, Y; Zhang, Z | 1 |
| Barroso-Chinea, P; Lanciego, JL; López, IP; Luis-Ravelo, D; Pérez-Manso, M; Rico, AJ; Roda, E | 1 |
| Flajolet, M; Greengard, P; Shen, W; Surmeier, DJ | 1 |
| Bérubé-Carrière, N; Dal Bo, G; Descarries, L; Leo, D; Lévesque, D; Mendez, JA; Riad, M; Trudeau, LE | 1 |
| Ardestani, MS; Moghaddamt, HF; Navidpour, L; Rahmim, A; Saffari, M; Shafiee, A | 1 |
| Bertrand, A; Boulet, S; Féger, J; Feuerstein, C; François, C; Hirsch, EC; Jan, C; Mounayar, S; Pessiglione, M; Poupard, A; Savasta, M; Tremblay, L | 1 |
| Marti, M; Morari, M; Trapella, C | 1 |
| Mabrouk, OS; Marti, M; Morari, M; Volta, M | 1 |
| Freund, HJ; Klosterkoetter, J; Kuhn, J; Lenartz, D; Mai, JK; Schnell, T; Sturm, V | 1 |
| Beales, M; Meredith, GE; Meshul, CK; Totterdell, S | 1 |
| Mabrouk, OS; Marti, M; Morari, M; Salvadori, S | 1 |
| Mabrouk, OS; Marti, M; Morari, M | 1 |
| Bilbe, G; Di Paolo, T; Gasparini, F; Gomez-Mancilla, B; Grégoire, L; Hornykiewicz, O; Johns, DR; Morissette, M; Ouattara, B; Rajput, A; Rajput, AH; Vranesic, I | 1 |
| Deutch, AY; Garcia, BG; Neely, MD | 1 |
| Black, YD; Brownell, AL; Kachroo, A; Pellegrino, D; Schwarzschild, MA; Xiao, D | 1 |
| Brotchie, JM; Johnston, TH; Kamal, M; Khademullah, CS; Lam, D; Lo, C; Nash, JE; Perera, G; Reyes, G; Sun, XS; Talwar, S; Thiele, S; Wang, S; Warre, R | 1 |
| Barroso-Chinea, P; Conte-Perales, L; Gómez-Bautista, V; Lanciego, JL; Luquin, N; Rico, AJ; Roda, E; Sierra, S | 1 |
| Dziubina, A; Gołembiowska, K | 1 |
| Antonelli, T; Beggiato, S; Ferraro, L; Fuxe, K; O'Connor, WT; Tanganelli, S; Tomasini, MC | 1 |
| Aguiar, AS; Castro, AA; Ferreira, J; Figueiredo, CP; Matheus, FC; Prediger, RD; Santos, AR; Tasca, CI; Villarinho, JG; Walz, R | 1 |
| Bari, M; Battista, N; Bernardi, G; Calabresi, P; Centonze, D; Finazzi-Agrò, A; Gubellini, P; Maccarrone, M; Picconi, B | 2 |
| Inoue, O; Kagawa, S; Nakano, T; Nishimura, T | 1 |
| Archer, T; Fredriksson, A; Palomo, T | 1 |
| During, MJ; Fitzsimons, HL; Kaplitt, MG; Liu, Y; Luo, J; Oshinsky, ML; Zuzga, DS | 1 |
| Beani, L; Bianchi, C; Marti, M; Mela, F; Morari, M | 1 |
| Dunnett, SB; Fawcettt, JW; Schwiening, CJ; Sinclair, SR; Zietlow, R | 1 |
| Beani, L; Bianchi, C; Marti, M; Mela, F; Morari, M; Paganini, F; Stocchi, S | 1 |
| Alessandrí, MG; Fornai, F; Geppert, M; Jahn, R; Schlüter, OM; Südhof, TC; Takamori, S | 1 |
| Fujimaru, S; Matsubara, K; Ohtaki, K; Saito, O; Shimizu, K; Shiono, H | 1 |
| Becker, H; Blin, O; Micallef, J; Tardieu, S | 1 |
| Bertrand, A; Bruet, N; Carcenac, C; Feuerstein, C; Poupard, A; Savasta, M; Windels, F | 1 |
| Frederickson, J; Meshul, CK; Moore, C; Touchon, JC | 1 |
| Kase, H; Ochi, M; Shiozaki, S | 2 |
| Beales, M; Dervan, AG; McBean, GJ; Meredith, GE; Meshul, CK; Moore, C; Snyder, AK; Totterdell, S | 1 |
| Bielicki, G; Chassain, C; Donnat, JP; Durif, F; Eschalier, A; Renou, JP | 1 |
| Holmer, HK; Keyghobadi, M; Menashe, RA; Meshul, CK; Moore, C | 1 |
| Ding, JH; Ellsworth, K; He, HR; Hu, G; Meng, CH; Wu, J; Yang, YL | 1 |
| Ding, JH; Hu, G; Hu, LF; Liu, SY; Sun, T; Sun, YH; Wang, S; Wu, J; Zhang, Y | 1 |
| Halliwell, B; Hyun, DH; Jenner, P; Lee, M | 1 |
| Annesi, F; Annesi, G; Arabia, G; Caracciolo, M; Cirò Candiano, IC; Civitelli, D; D'Amelio, M; Fierro, B; La Bella, V; Piccoli, F; Piccoli, T; Pugliese, P; Quattrone, A; Ragonese, P; Savettieri, G; Tarantino, P | 1 |
| Elsaesser, VE; Foroud, T; Halter, CA; Marek, DK; Nichols, WC; Pankratz, N; Pauciulo, MW; Rudolph, A; Shults, CW; Wojcieszek, J | 1 |
| Konieczny, J; Kuter, K; Ossowska, K; Pilc, A; Wardas, J | 1 |
| Marti, M; Morari, M; Trapella, C; Viaro, R | 1 |
| Dorman, DC; McManus, BE; Struve, MF; Wong, BA | 1 |
| Croucher, MJ; Datla, KP; Dexter, DT; Vernon, AC; Zbarsky, V | 1 |
| Bielicki, G; Chassain, C; Durand, E; Durif, F; Essafi, F; Lolignier, S; Traoré, A | 1 |
| Fernández-Ruiz, J; Ferraro, L; García-Arencibia, M; Tanganelli, S | 1 |
| Allen, C; Meshul, CK | 1 |
| Beani, L; Bianchi, C; Fuxe, K; Marti, M; Morari, M; Sbrenna, S | 1 |
| Chase, TN; Oh, JD | 1 |
| Giacomini, P; Lavaroni, F; Morello, M; Sancesario, G; Spadoni, F; Stefani, A | 1 |
| Ferger, B; Schmidt, N | 1 |
| Blandini, F; Fancellu, R; Greenamyre, JT; Nappi, G | 1 |
| Benabid, AL; Benazzouz, A; Bouali-Benazzouz, R; Gao, D; Ni, Z | 1 |
| Araki, T; Imai, Y; Matsubara, M; Muramatsu, Y; Tanaka, K | 1 |
| Araki, T; Imai, Y; Itoyama, Y; Kato, H; Kumagai, T; Matsubara, M; Tanaka, K | 1 |
| Eto, H; Hayase, N; Kimura, K; Matsubara, K; Mizukami, H; Ogawa, K; Saito, O; Shimizu, K; Shiono, H; Uezono, T | 1 |
| Chen, L; Li, S; Liu, Z; Tian, Z; Wang, Y | 1 |
| Ebinger, G; Jonkers, N; Michotte, Y; Sarre, S | 1 |
| Bédard, PJ; Blanchet, PJ; Calon, F; Di Paolo, T; Ghribi, O; Goulet, M; Grondin, R; Morissette, M | 1 |
4 review(s) available for glutamic acid and Autosomal Dominant Juvenile Parkinson Disease
| Article | Year |
|---|---|
Role of nitric oxide in the regulation of motor function. An overview of behavioral, biochemical and histological studies in animal models.
Topics: Animals; Behavior, Animal; Brain; Cyclic GMP; Disease Models, Animal; Dopamine; Enzyme Inhibitors; Glutamic Acid; Guanylate Cyclase; Motor Activity; Motor Neurons; Nitrergic Neurons; Nitric Oxide; Nitric Oxide Donors; Nitric Oxide Synthase Type I; Parkinsonian Disorders; Receptors, Cytoplasmic and Nuclear; Soluble Guanylyl Cyclase; Synaptic Transmission | 2013 |
Manganese-Induced Parkinsonism and Parkinson's Disease: Shared and Distinguishable Features.
Topics: Brain; Dopamine; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Magnesium; Manganese Poisoning; Parkinson Disease; Parkinsonian Disorders | 2015 |
[Treatment of non-dopamine-dependent signs in parkinsonian syndromes: evaluation and results].
Topics: Anti-Dyskinesia Agents; Botulinum Toxins; Cholinesterase Inhibitors; Clozapine; Dementia; Depressive Disorder; Dopamine; Glutamic Acid; Humans; Movement Disorders; Parkinsonian Disorders; Selective Serotonin Reuptake Inhibitors; Serotonin; Synaptic Transmission; Treatment Outcome | 2003 |
Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dopamine; Glutamic Acid; Humans; Levodopa; Models, Neurological; Neurons, Efferent; Parkinsonian Disorders; Phosphotransferases; Receptors, Dopamine; Receptors, Glutamate; Signal Transduction | 2000 |
1 trial(s) available for glutamic acid and Autosomal Dominant Juvenile Parkinson Disease
| Article | Year |
|---|---|
Cognitive functions in a patient with Parkinson-dementia syndrome undergoing deep brain stimulation.
Topics: Acetylcholine; Aged; Arousal; Attention; Basal Nucleus of Meynert; Cholinergic Fibers; Cognition; Cognition Disorders; Deep Brain Stimulation; Double-Blind Method; Electrodes, Implanted; gamma-Aminobutyric Acid; Glutamic Acid; Humans; Lewy Body Disease; Male; Neuropsychological Tests; Parkinsonian Disorders; Prospective Studies; Recovery of Function; Social Behavior; Subthalamic Nucleus; Treatment Outcome | 2009 |
91 other study(ies) available for glutamic acid and Autosomal Dominant Juvenile Parkinson Disease
| Article | Year |
|---|---|
Genetic deletion of GPR88 enhances the locomotor response to L-DOPA in experimental parkinsonism while counteracting the induction of dyskinesia.
Topics: Adrenergic Agents; Animals; Antiparkinson Agents; Cholinesterase Inhibitors; Corpus Striatum; Dopamine Plasma Membrane Transport Proteins; Dyskinesia, Drug-Induced; GABAergic Neurons; Glutamic Acid; Levodopa; Locomotion; Male; Medial Forebrain Bundle; Mice; Mice, Knockout; Movement; Neuronal Plasticity; Oxidopamine; Parkinsonian Disorders; Receptors, G-Protein-Coupled; RNA, Messenger; Serotonin; Tacrine; Tremor | 2020 |
Thalamic degeneration in MPTP-treated Parkinsonian monkeys: impact upon glutamatergic innervation of striatal cholinergic interneurons.
Topics: Animals; Caudate Nucleus; Cholinergic Neurons; Female; Glutamic Acid; Interneurons; Intralaminar Thalamic Nuclei; Macaca mulatta; Male; Neural Pathways; Neurons; Parkinsonian Disorders; Putamen; Synapses; Vesicular Glutamate Transport Protein 2 | 2019 |
Calcium Salt of N-(5-Hydroxynicotinoyl)-L-Glutamic Acid Weakens Depressive-Like Behavior and Parkinsonian Syndrome in Experiment on Rodents.
Topics: Animals; Antidepressive Agents; Calcium; Catalepsy; Depression; Glutamic Acid; Haloperidol; Male; Mice; Mice, Inbred C57BL; Parkinsonian Disorders | 2019 |
Structural plasticity of GABAergic and glutamatergic networks in the motor thalamus of parkinsonian monkeys.
Topics: Animals; Female; GABAergic Neurons; Glutamic Acid; Macaca mulatta; Male; Nerve Net; Parkinsonian Disorders; Ventral Thalamic Nuclei; Vesicular Glutamate Transport Protein 1 | 2020 |
Safinamide inhibits in vivo glutamate release in a rat model of Parkinson's disease.
Topics: Alanine; Animals; Benzylamines; Excitatory Amino Acid Antagonists; Glutamic Acid; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley | 2020 |
Effects of safinamide on the glutamatergic striatal network in experimental Parkinson's disease.
Topics: Alanine; Animals; Antiparkinson Agents; Benzylamines; Corpus Striatum; Dose-Response Relationship, Drug; Excitatory Postsynaptic Potentials; Glutamic Acid; Levodopa; Male; Nerve Net; Organ Culture Techniques; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar | 2020 |
Striatal and nigral muscarinic type 1 and type 4 receptors modulate levodopa-induced dyskinesia and striato-nigral pathway activation in 6-hydroxydopamine hemilesioned rats.
Topics: Allosteric Regulation; Animals; Dopamine Agents; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Microdialysis; Muscarinic Antagonists; Neostriatum; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Rats; Receptor, Muscarinic M1; Receptor, Muscarinic M4; Substantia Nigra; Sympatholytics | 2020 |
Effect of Anti-Glutamate Antibodies in Modeled Parkinsonian Syndrome.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Animals; Antibodies; Antiparkinson Agents; Autoantibodies; Dopamine; gamma-Globulins; Glutamic Acid; Horses; Hypokinesia; Immunoconjugates; Male; Mice; Mice, Inbred C57BL; Parkinsonian Disorders; Rabbits | 2020 |
Loss of nigral excitation of cholinergic interneurons contributes to parkinsonian motor impairments.
Topics: Acetylcholine; Animals; Behavior, Animal; Dopamine; Female; Glutamic Acid; Interneurons; Male; Mice; Mice, Inbred C57BL; Motor Disorders; Neostriatum; Parasympathetic Nervous System; Parkinsonian Disorders; Receptors, AMPA; Substantia Nigra; Synapses; Synaptic Transmission | 2021 |
Downregulation of astroglial glutamate transporter GLT-1 in the lateral habenula is associated with depressive-like behaviors in a rat model of Parkinson's disease.
Topics: Animals; Astrocytes; Depression; Disease Models, Animal; Down-Regulation; Excitatory Amino Acid Transporter 2; Glutamic Acid; Habenula; Oxidopamine; Parkinsonian Disorders; Pars Compacta; Rats; Substantia Nigra; Thalamus; Ventral Tegmental Area | 2021 |
Microglia may compensate for dopaminergic neuron loss in experimental Parkinsonism through selective elimination of glutamatergic synapses from the subthalamic nucleus.
Topics: Animals; Animals, Newborn; Cells, Cultured; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Exploratory Behavior; Glutamic Acid; Male; Microglia; Motor Activity; Oxidopamine; Parkinsonian Disorders; Phagocytosis; Prosencephalon; Rats; Rats, Wistar; Subthalamic Nucleus; Sympatholytics; Synapses | 2017 |
Activation and blockade of basolateral amygdala 5-HT
Topics: Animals; Anti-Anxiety Agents; Anxiety; Basolateral Nuclear Complex; Corpus Striatum; Dopamine; gamma-Aminobutyric Acid; Glutamic Acid; Male; Methylamines; Neural Pathways; Neurons; Norepinephrine; Oxidopamine; Parkinsonian Disorders; Piperazines; Pyridines; Rats, Sprague-Dawley; Receptors, Serotonin; Serotonin Agents; Substantia Nigra; Sulfonamides | 2018 |
Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's disease.
Topics: Animals; Corpus Striatum; Dopamine Agonists; Excitatory Postsynaptic Potentials; Glutamic Acid; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Parkinsonian Disorders; Quinpirole; Receptors, Dopamine D2; Synaptic Transmission | 2018 |
Glutamate and GABA neurotransmission are increased in paraventricular nucleus of hypothalamus in rats induced to 6-OHDA parkinsonism: Involvement of nNOS.
Topics: Animals; Blood Pressure; Cardiovascular System; gamma-Aminobutyric Acid; Glutamic Acid; Heart Rate; Male; Neurodegenerative Diseases; Nitric Oxide Synthase Type I; Paraventricular Hypothalamic Nucleus; Parkinsonian Disorders; Rats, Wistar | 2019 |
Cortical glutamate levels decrease in a non-human primate model of dopamine deficiency.
Topics: Animals; Biosensing Techniques; Cell Count; Dopamine; Dopaminergic Neurons; Electrodes, Implanted; Female; Glutamic Acid; Macaca mulatta; Microelectrodes; Motor Cortex; Nerve Tissue Proteins; Parkinsonian Disorders; Substantia Nigra; Tyrosine 3-Monooxygenase | 2014 |
GluN2D-containing NMDA receptors inhibit neurotransmission in the mouse striatum through a cholinergic mechanism: implication for Parkinson's disease.
Topics: Acetylcholine; Action Potentials; Animals; Corpus Striatum; Depression, Chemical; Dopamine; Glutamic Acid; Interneurons; Male; Mice; Mice, Inbred C57BL; Models, Neurological; Muscarinic Agonists; Muscarinic Antagonists; Oxidopamine; Parkinsonian Disorders; Patch-Clamp Techniques; Receptors, N-Methyl-D-Aspartate; Secretory Rate; Synaptic Transmission | 2014 |
NMDA receptor antagonism potentiates the L-DOPA-induced extracellular dopamine release in the subthalamic nucleus of hemi-parkinson rats.
Topics: Animals; Antiparkinson Agents; Disease Models, Animal; Dizocilpine Maleate; Dopamine; Excitatory Amino Acid Antagonists; Extracellular Space; Functional Laterality; Glutamic Acid; Levodopa; Male; Microdialysis; Oxidopamine; Parkinsonian Disorders; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Substantia Nigra; Subthalamic Nucleus | 2014 |
Distinct effects of mGlu4 receptor positive allosteric modulators at corticostriatal vs. striatopallidal synapses may differentially contribute to their antiparkinsonian action.
Topics: Amino Acid Transport System X-AG; Anilides; Animals; Antiparkinson Agents; Brain; Cerebral Cortex; Corpus Striatum; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dopamine Antagonists; Excitatory Amino Acid Agents; Globus Pallidus; Glutamic Acid; Haloperidol; Male; Oxidopamine; Parkinsonian Disorders; Rats, Wistar; Receptors, Metabotropic Glutamate; Synapses; Synaptic Transmission; Tissue Culture Techniques | 2014 |
The possible mechanism of Parkinson's disease progressive damage and the preventive effect of GM1 in the rat model induced by 6-hydroxydopamine.
Topics: Animals; bcl-2-Associated X Protein; Brain; Calcium; Calmodulin; Disease Progression; G(M1) Ganglioside; Glutamic Acid; Infusions, Parenteral; Male; Malondialdehyde; Mitochondria; Neuroprotective Agents; Nitric Oxide Synthase Type I; Oxidopamine; Parkinsonian Disorders; Proto-Oncogene Proteins c-bcl-2; Rats, Wistar; Trace Elements | 2014 |
Heterosynaptic regulation of external globus pallidus inputs to the subthalamic nucleus by the motor cortex.
Topics: Animals; Dopamine; GABAergic Neurons; gamma-Aminobutyric Acid; Globus Pallidus; Glutamic Acid; Long-Term Potentiation; Mice; Motor Cortex; Neural Pathways; Neuronal Plasticity; Optogenetics; Parkinsonian Disorders; Receptors, GABA-A; Receptors, N-Methyl-D-Aspartate; Subthalamic Nucleus; Synaptic Transmission | 2015 |
Striking the right balance: cortical modulation of the subthalamic nucleus-globus pallidus circuit.
Topics: Animals; Dopamine; gamma-Aminobutyric Acid; Globus Pallidus; Glutamic Acid; Motor Cortex; Neural Pathways; Parkinsonian Disorders; Subthalamic Nucleus | 2015 |
Interaction between hyperdirect and indirect basal ganglia pathways.
Topics: Animals; Dopamine; gamma-Aminobutyric Acid; Globus Pallidus; Glutamic Acid; Motor Cortex; Neural Pathways; Parkinsonian Disorders; Subthalamic Nucleus | 2015 |
Alterations in the motor cortical and striatal glutamatergic system and D-serine levels in the bilateral 6-hydroxydopamine rat model for Parkinson's disease.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Glutamic Acid; Male; Motor Cortex; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Serine | 2015 |
Modulation by Trace Amine-Associated Receptor 1 of Experimental Parkinsonism, L-DOPA Responsivity, and Glutamatergic Neurotransmission.
Topics: Adrenergic Agents; Akathisia, Drug-Induced; Animals; Antiparkinson Agents; Cocaine; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; Dopamine Plasma Membrane Transport Proteins; Glutamic Acid; Levodopa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oligodeoxyribonucleotides, Antisense; Oxidopamine; Parkinsonian Disorders; Radiopharmaceuticals; Receptors, G-Protein-Coupled; Stereotyped Behavior; Synaptic Transmission; Time Factors; Tyrosine 3-Monooxygenase | 2015 |
Functional modulation of G-protein coupled receptors during Parkinson disease-like neurodegeneration.
Topics: Animals; CHO Cells; Cricetinae; Cricetulus; Dose-Response Relationship, Drug; Glutamic Acid; Male; Neurodegenerative Diseases; Parkinsonian Disorders; Protein Binding; Rats; Rats, Sprague-Dawley; Receptors, G-Protein-Coupled; Receptors, Metabotropic Glutamate | 2016 |
M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia.
Topics: Allosteric Regulation; Animals; Cerebral Cortex; Disease Models, Animal; Dopamine Agents; Dyskinesia, Drug-Induced; Glutamic Acid; Levodopa; Long-Term Potentiation; Long-Term Synaptic Depression; Macaca mulatta; Mice; Mice, Transgenic; Neostriatum; Neuronal Plasticity; Neurons; Parkinsonian Disorders; Receptor, Muscarinic M4; RGS Proteins; Signal Transduction | 2015 |
The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements.
Topics: Animals; Anti-Dyskinesia Agents; Corpus Striatum; Cross-Over Studies; Dopamine; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Dyskinesia, Drug-Induced; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Male; Microdialysis; Oxidopamine; Parkinsonian Disorders; Piperidines; Pyridines; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonin; Serotonin 5-HT1 Receptor Agonists | 2016 |
Early increase in dopamine release in the ipsilateral striatum after unilateral intranigral administration of lactacystin produces spontaneous contralateral rotations in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcysteine; Amphetamine; Animals; Benzazepines; Central Nervous System Agents; Corpus Striatum; Dopamine; Dopamine Antagonists; Functional Laterality; Glutamic Acid; Haloperidol; Homovanillic Acid; Male; Movement; Parkinsonian Disorders; Rats, Wistar; Receptors, Dopamine; Rotation; Substantia Nigra | 2016 |
The Role of Group II Metabotropic Glutamate Receptors in the Striatum in Electroacupuncture Treatment of Parkinsonian Rats.
Topics: Analysis of Variance; Animals; Chromatography, High Pressure Liquid; Corpus Striatum; Disease Models, Animal; Electroacupuncture; Excitatory Amino Acid Agents; Gene Expression Regulation; Glutamic Acid; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate; RNA, Messenger; Sympatholytics; Time Factors; Tyrosine 3-Monooxygenase | 2017 |
Neuropeptide cycloprolylglycine increases the levels of brain-derived neurotrophic factor in neuronal cells.
Topics: Animals; Brain-Derived Neurotrophic Factor; Cell Line; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Glutamic Acid; Hippocampus; Humans; Mice; Neurons; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Peptides, Cyclic; Piracetam | 2016 |
The Role of Primary Motor Cortex (M1) Glutamate and GABA Signaling in l-DOPA-Induced Dyskinesia in Parkinsonian Rats.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Excitatory Amino Acid Agents; GABA Agents; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Male; Motor Cortex; Movement; Oxidopamine; Parkinsonian Disorders; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Signal Transduction; Sympatholytics; Tardive Dyskinesia | 2016 |
Altered glutamate release in the dorsal striatum of the MitoPark mouse model of Parkinson's disease.
Topics: Animals; Corpus Striatum; Dopamine; Excitatory Amino Acid Transporter 2; Glial Fibrillary Acidic Protein; Glutamic Acid; Kinetics; Male; Mice, Transgenic; Mitochondria; Nerve Degeneration; Neurotransmitter Agents; Parkinsonian Disorders; Potassium Chloride; Receptor, Metabotropic Glutamate 5; Synaptic Transmission | 2016 |
Intrastriatal injection of ionomycin profoundly changes motor response to l-DOPA and its underlying molecular mechanisms.
Topics: Animals; Antiparkinson Agents; Calcineurin; Calcium Ionophores; Corpus Striatum; Dopamine; Dopamine and cAMP-Regulated Phosphoprotein 32; Dyskinesia, Drug-Induced; Glutamic Acid; Ionomycin; Levodopa; Male; MAP Kinase Signaling System; Parkinsonian Disorders; Phosphorylation; Proto-Oncogene Proteins c-fos; Random Allocation; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate | 2017 |
Glutamatergic pallidothalamic projections and their implications in the pathophysiology of Parkinson's disease.
Topics: Animals; Dopamine; Down-Regulation; Efferent Pathways; Entopeduncular Nucleus; gamma-Aminobutyric Acid; Gene Expression Regulation, Enzymologic; Globus Pallidus; Glutamate Decarboxylase; Glutamic Acid; Male; Parkinsonian Disorders; Rats; Rats, Wistar; RNA, Messenger; Substantia Nigra; Synaptic Transmission; Thalamus; Up-Regulation; Vesicular Glutamate Transport Protein 2 | 2008 |
Dichotomous dopaminergic control of striatal synaptic plasticity.
Topics: Animals; Cannabinoid Receptor Modulators; Corpus Striatum; Dopamine; Glutamic Acid; Long-Term Potentiation; Long-Term Synaptic Depression; Mice; Mice, Transgenic; Neurons; Parkinsonian Disorders; Receptors, Dopamine D1; Receptors, Dopamine D2; Signal Transduction; Synapses | 2008 |
Enhanced glutamatergic phenotype of mesencephalic dopamine neurons after neonatal 6-hydroxydopamine lesion.
Topics: Animals; Animals, Newborn; Disease Models, Animal; Dopamine; Glutamic Acid; Male; Mesencephalon; Nerve Degeneration; Neural Pathways; Neuronal Plasticity; Neurons; Nucleus Accumbens; Oxidopamine; Parkinsonian Disorders; Phenotype; Presynaptic Terminals; Rats; Rats, Sprague-Dawley; RNA, Messenger; Substantia Nigra; Sympatholytics; Tyrosine 3-Monooxygenase; Ventral Tegmental Area; Vesicular Glutamate Transport Protein 2 | 2008 |
Dopaminergic but not glutamatergic neurotransmission is increased in the striatum after selective cyclooxygenase-2 inhibition in normal and hemiparkinsonian rats.
Topics: Animals; Celecoxib; Corpus Striatum; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Glutamic Acid; Male; Microdialysis; Oxidopamine; Parkinsonian Disorders; Pyrazoles; Rats; Rats, Wistar; Substantia Nigra; Sulfonamides; Synaptic Transmission | 2008 |
Behavioral recovery in MPTP-treated monkeys: neurochemical mechanisms studied by intrastriatal microdialysis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Chlorocebus aethiops; Corpus Striatum; Disease Models, Animal; Dopamine; Down-Regulation; Extracellular Fluid; gamma-Aminobutyric Acid; Glutamic Acid; Homovanillic Acid; Hydroxyindoleacetic Acid; Male; Microdialysis; Movement; Neurotransmitter Agents; Parkinsonian Disorders; Recovery of Function; Serotonin; Up-Regulation | 2008 |
The novel nociceptin/orphanin FQ receptor antagonist Trap-101 alleviates experimental parkinsonism through inhibition of the nigro-thalamic pathway: positive interaction with L-DOPA.
Topics: Animals; Antiparkinson Agents; Benzimidazoles; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interactions; Dyskinesia, Drug-Induced; Functional Laterality; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Mice; Mice, Inbred C57BL; Mice, Knockout; Microdialysis; Motor Activity; Narcotic Antagonists; Neural Pathways; Nociceptin Receptor; Oxidopamine; Parkinsonian Disorders; Psychomotor Performance; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Opioid; Substantia Nigra; Thalamus; Time Factors | 2008 |
Stimulation of delta opioid receptors located in substantia nigra reticulata but not globus pallidus or striatum restores motor activity in 6-hydroxydopamine lesioned rats: new insights into the role of delta receptors in parkinsonism.
Topics: Analysis of Variance; Animals; Behavior, Animal; Benzamides; Bicuculline; Bridged Bicyclo Compounds, Heterocyclic; Chromatography, High Pressure Liquid; Disease Models, Animal; Dose-Response Relationship, Drug; GABA Antagonists; gamma-Aminobutyric Acid; Glutamic Acid; Hindlimb Suspension; Male; Microdialysis; Motor Activity; Oxidopamine; Parkinsonian Disorders; Piperazines; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Receptors, Opioid, delta; Substantia Nigra; Thiophenes; Time Factors | 2008 |
Impaired glutamate homeostasis and programmed cell death in a chronic MPTP mouse model of Parkinson's disease.
Topics: Adjuvants, Pharmaceutic; Animals; Apoptosis; Autophagy; Biological Transport, Active; Disease Models, Animal; Dopamine; Extracellular Fluid; Glutamic Acid; Homeostasis; Male; Mice; Mice, Inbred C57BL; Neurons; Parkinsonian Disorders; Probenecid; Signal Transduction; Substantia Nigra; Up-Regulation; Vesicular Glutamate Transport Proteins | 2009 |
The novel delta opioid receptor agonist UFP-512 dually modulates motor activity in hemiparkinsonian rats via control of the nigro-thalamic pathway.
Topics: Amino Acids; Animals; Antiparkinson Agents; Benzimidazoles; Dose-Response Relationship, Drug; gamma-Aminobutyric Acid; Globus Pallidus; Glutamic Acid; Male; Motor Activity; Naltrexone; Narcotic Antagonists; Neural Pathways; Oligopeptides; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Opioid, delta; Substantia Nigra; Thalamus | 2009 |
Endogenous nociceptin/orphanin FQ (N/OFQ) contributes to haloperidol-induced changes of nigral amino acid transmission and parkinsonism: a combined microdialysis and behavioral study in naïve and nociceptin/orphanin FQ receptor knockout mice.
Topics: Animals; Antipsychotic Agents; Benzimidazoles; Disease Models, Animal; Dose-Response Relationship, Drug; Dyskinesia, Drug-Induced; Extracellular Fluid; gamma-Aminobutyric Acid; Glutamic Acid; Haloperidol; Mice; Mice, Inbred C57BL; Mice, Knockout; Microdialysis; Narcotic Antagonists; Neuropharmacology; Nociceptin; Nociceptin Receptor; Opioid Peptides; Parkinsonian Disorders; Piperidines; Receptors, Opioid; Substantia Nigra; Synaptic Transmission | 2010 |
Metabotropic glutamate receptor type 5 in levodopa-induced motor complications.
Topics: Aged; Aged, 80 and over; Animals; Antiparkinson Agents; Cohort Studies; Corpus Striatum; Dyskinesia, Drug-Induced; Female; Glutamic Acid; Humans; Levodopa; Macaca fascicularis; Parkinsonian Disorders; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate; Up-Regulation | 2011 |
Cortical regulation of striatal medium spiny neuron dendritic remodeling in parkinsonism: modulation of glutamate release reverses dopamine depletion-induced dendritic spine loss.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Cerebral Cortex; Corpus Striatum; Dendrites; Disease Models, Animal; Dopamine; Excitatory Amino Acid Agents; Fluoresceins; Glutamic Acid; Male; Neurons; Organ Culture Techniques; Organic Chemicals; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Silver Staining | 2010 |
Protective effect of metabotropic glutamate mGluR5 receptor elimination in a 6-hydroxydopamine model of Parkinson's disease.
Topics: Animals; Cytoprotection; Disease Models, Animal; Glutamic Acid; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxidopamine; Parkinsonian Disorders; Receptor, Metabotropic Glutamate 5; Receptors, Metabotropic Glutamate | 2010 |
Altered function of glutamatergic cortico-striatal synapses causes output pathway abnormalities in a chronic model of parkinsonism.
Topics: Animals; Cerebral Cortex; Chronic Disease; Corpus Striatum; Disease Models, Animal; Excitatory Postsynaptic Potentials; Glutamic Acid; Mice; Mice, Transgenic; Neural Pathways; Parkinsonian Disorders; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Synapses | 2011 |
Glutamatergic and cholinergic pedunculopontine neurons innervate the thalamic parafascicular nucleus in rats: changes following experimental parkinsonism.
Topics: Animals; Cholinergic Neurons; DNA Primers; Glutamic Acid; Histological Techniques; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; Intralaminar Thalamic Nuclei; Microdissection; Neurons, Efferent; Parkinsonian Disorders; Pedunculopontine Tegmental Nucleus; Polymerase Chain Reaction; Rats; RNA, Messenger; Stilbamidines; Vesicular Glutamate Transport Protein 2 | 2011 |
Effect of adenosine A(2A) receptor antagonists and L-DOPA on hydroxyl radical, glutamate and dopamine in the striatum of 6-OHDA-treated rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Animals; Benserazide; Caffeine; Dopamine; Glutamic Acid; Hydroxyl Radical; Levodopa; Male; Microdialysis; Neostriatum; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Receptor, Adenosine A2A; Triazines; Triazoles | 2012 |
Striatal NTS1 , dopamine D2 and NMDA receptor regulation of pallidal GABA and glutamate release--a dual-probe microdialysis study in the intranigral 6-hydroxydopamine unilaterally lesioned rat.
Topics: Adrenergic Agents; Animals; Corpus Striatum; gamma-Aminobutyric Acid; Globus Pallidus; Glutamic Acid; Male; Microdialysis; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate; Receptors, Neurotensin; Synaptic Transmission | 2012 |
Neuroprotective effects of agmatine in mice infused with a single intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Agmatine; Analysis of Variance; Animals; Disease Models, Animal; Dopaminergic Neurons; Drug Administration Schedule; Drug Interactions; Exploratory Behavior; Female; Glutamic Acid; Hippocampus; Mice; Mice, Inbred C57BL; Motor Activity; Neurologic Examination; Neuroprotective Agents; Parkinsonian Disorders; Recognition, Psychology; Social Behavior; Substantia Nigra; Survival Analysis; Tritium; Tyrosine 3-Monooxygenase | 2012 |
Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission.
Topics: Amidohydrolases; Animals; Arachidonic Acids; Cannabinoid Receptor Modulators; Cannabinoids; Carrier Proteins; Corpus Striatum; Disease Models, Animal; Dronabinol; Endocannabinoids; Enzyme Inhibitors; Glutamic Acid; Glycerides; Hydrolysis; In Vitro Techniques; Membrane Potentials; Neurons; Oxidopamine; Parkinsonian Disorders; Patch-Clamp Techniques; Polyunsaturated Alkamides; Rats; Rats, Wistar; Receptors, Cannabinoid; Receptors, Drug; Synaptic Transmission | 2002 |
Effect of glutamatergic systems on in vivo binding of [(125)I]beta-CIT in the brain of a rat model of Parkinson's disease.
Topics: Animals; Autoradiography; Binding, Competitive; Cocaine; Disease Models, Animal; Dizocilpine Maleate; Dopamine; Excitatory Amino Acid Antagonists; Glutamic Acid; In Vitro Techniques; Iodine Radioisotopes; Male; Neurons; Oxidopamine; Parkinsonian Disorders; Radionuclide Imaging; Radiopharmaceuticals; Rats; Rats, Wistar; Serotonin; Sympatholytics | 2002 |
Restorative effects of glutamate antagonists in experimental parkinsonism.
Topics: Animals; Anticonvulsants; Antiparkinson Agents; Corpus Striatum; Dopamine; Excitatory Amino Acid Antagonists; Glutamic Acid; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Parkinsonian Disorders; Receptors, N-Methyl-D-Aspartate | 2002 |
Subthalamic GAD gene therapy in a Parkinson's disease rat model.
Topics: Animals; Dependovirus; Disease Models, Animal; Dopamine; Electric Stimulation; Electrophysiology; gamma-Aminobutyric Acid; Genetic Therapy; Genetic Vectors; Glutamate Decarboxylase; Glutamic Acid; Humans; Ibotenic Acid; Isoenzymes; Male; Mesencephalon; Mice; Motor Activity; Nerve Degeneration; Neurons; Oxidopamine; Parkinsonian Disorders; Phenotype; Rats; Stem Cells; Substantia Nigra; Subthalamic Nucleus; Synaptic Transmission; Transgenes | 2002 |
Striatal dopamine-NMDA receptor interactions in the modulation of glutamate release in the substantia nigra pars reticulata in vivo: opposite role for D1 and D2 receptors.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Antagonists; Dopamine D2 Receptor Antagonists; Glutamic Acid; Male; Microdialysis; N-Methylaspartate; Oxidopamine; Parkinsonian Disorders; Perfusion; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Receptors, N-Methyl-D-Aspartate; Substantia Nigra; Wakefulness | 2002 |
The release of excitatory amino acids, dopamine, and potassium following transplantation of embryonic mesencephalic dopaminergic grafts to the rat striatum, and their effects on dopaminergic neuronal survival in vitro.
Topics: Animals; Aspartic Acid; Cell Death; Corpus Striatum; Dopamine; Excitatory Amino Acids; Extracellular Space; Female; Glutamic Acid; Graft Survival; Neurons; Parkinsonian Disorders; Potassium; Rats; Rats, Inbred Strains; Stem Cell Transplantation; Stem Cells; Substantia Nigra | 2002 |
Plasticity of glutamatergic control of striatal acetylcholine release in experimental parkinsonism: opposite changes at group-II metabotropic and NMDA receptors.
Topics: Acetylcholine; Animals; Antiparkinson Agents; Benserazide; Corpus Striatum; Drug Therapy, Combination; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Glutamic Acid; Levodopa; Male; N-Methylaspartate; Neuronal Plasticity; Parkinsonian Disorders; Potassium; Rats; Rats, Sprague-Dawley; Receptors, Glutamate; Receptors, Metabotropic Glutamate; Receptors, N-Methyl-D-Aspartate; Synaptosomes | 2003 |
Levodopa treatment reverses endocannabinoid system abnormalities in experimental parkinsonism.
Topics: Amidohydrolases; Animals; Antiparkinson Agents; Arachidonic Acids; Binding, Competitive; Cannabinoid Receptor Modulators; Cerebellum; Corpus Striatum; Cyclohexanols; Disease Models, Animal; Endocannabinoids; Excitatory Postsynaptic Potentials; Fatty Acids, Unsaturated; Glutamic Acid; Glycerides; In Vitro Techniques; Levodopa; Oxidopamine; Parkinsonian Disorders; Patch-Clamp Techniques; Phospholipase D; Polyunsaturated Alkamides; Rats; Rats, Wistar; Receptors, Cannabinoid; Receptors, Drug | 2003 |
Role of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Uptake Inhibitors; alpha-Synuclein; Animals; Antibodies; Blastomeres; Blotting, Southern; Corpus Striatum; Disease Models, Animal; DNA Primers; Dopamine; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Glutamic Acid; Hippocampus; Homovanillic Acid; Humans; Immunoblotting; Immunohistochemistry; Methamphetamine; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; MPTP Poisoning; Nerve Tissue Proteins; Neurons; Parkinsonian Disorders; Piperazines; Rats; Reserpine; Serotonin; Stem Cells; Subcellular Fractions; Substantia Nigra; Synucleins; Tyrosine 3-Monooxygenase | 2003 |
Paraquat induces long-lasting dopamine overflow through the excitotoxic pathway in the striatum of freely moving rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Corpus Striatum; Dizocilpine Maleate; Dopamine; Dopamine Plasma Membrane Transport Proteins; Enzyme Inhibitors; Excitatory Amino Acid Antagonists; Extracellular Space; Glutamic Acid; Herbicides; Homovanillic Acid; Male; Membrane Glycoproteins; Membrane Transport Proteins; Motor Activity; Nerve Tissue Proteins; Neuroprotective Agents; Neurotoxins; NG-Nitroarginine Methyl Ester; Nitric Oxide; Paraquat; Parkinsonian Disorders; Quinoxalines; Rats; Rats, Wistar; Selegiline | 2003 |
Neurochemical mechanisms induced by high frequency stimulation of the subthalamic nucleus: increase of extracellular striatal glutamate and GABA in normal and hemiparkinsonian rats.
Topics: Animals; Corpus Striatum; Electric Stimulation; Extracellular Fluid; gamma-Aminobutyric Acid; Glutamic Acid; Male; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Subthalamic Nucleus | 2003 |
Lesion of subthalamic or motor thalamic nucleus in 6-hydroxydopamine-treated rats: effects on striatal glutamate and apomorphine-induced contralateral rotations.
Topics: Animals; Apomorphine; Corpus Striatum; Glutamic Acid; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Subthalamic Nucleus | 2004 |
L-DOPA-induced modulation of GABA and glutamate release in substantia nigra pars reticulata in a rodent model of Parkinson's disease.
Topics: Animals; gamma-Aminobutyric Acid; Glutamic Acid; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Substantia Nigra | 2004 |
Adenosine A(2A) receptor-mediated modulation of GABA and glutamate release in the output regions of the basal ganglia in a rodent model of Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Animals; Basal Ganglia; Denervation; Disease Models, Animal; Efferent Pathways; Extracellular Fluid; gamma-Aminobutyric Acid; Globus Pallidus; Glutamic Acid; Male; Models, Neurological; Neostriatum; Neurons; Oxidopamine; Parkinsonian Disorders; Purines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Substantia Nigra | 2004 |
Astroglial plasticity and glutamate function in a chronic mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Astrocytes; Biological Transport; Cell Count; Cell Size; Chronic Disease; Disease Models, Animal; Disease Progression; Excitatory Amino Acid Transporter 2; Extracellular Fluid; Glial Fibrillary Acidic Protein; Gliosis; Glutamic Acid; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Neostriatum; Parkinsonian Disorders; Probenecid; Sodium; Synapses | 2004 |
Cerebral glutamate metabolism in Parkinson's disease: an in vivo dynamic (13)C NMS study in the rat.
Topics: Animals; Antiparkinson Agents; Basal Ganglia; Carbon Isotopes; Disease Models, Animal; Dopamine; Glutamic Acid; Glutaminase; Glutamine; Infusions, Intravenous; Levodopa; Lipid Metabolism; Magnetic Resonance Spectroscopy; Male; Neostriatum; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Sodium Acetate | 2005 |
Dietary restriction affects striatal glutamate in the MPTP-induced mouse model of nigrostriatal degeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Caloric Restriction; Corpus Striatum; Disease Models, Animal; Dopamine; Down-Regulation; Excitatory Amino Acid Transporter 2; Extracellular Fluid; Food Deprivation; Glutamic Acid; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Microdialysis; Microscopy, Electron, Transmission; Nerve Degeneration; Neural Pathways; Parkinsonian Disorders; Presynaptic Terminals; Substantia Nigra; Synaptic Transmission; Tyrosine 3-Monooxygenase | 2005 |
Iptakalim hydrochloride protects cells against neurotoxin-induced glutamate transporter dysfunction in in vitro and in vivo models.
Topics: Amino Acid Transport System X-AG; Animals; Cerebral Cortex; Disease Models, Animal; Glutamic Acid; Male; Neostriatum; Neuroprotective Agents; Neurotoxins; Parkinsonian Disorders; PC12 Cells; Potassium Channels; Propylamines; Rats; Rats, Sprague-Dawley; Synaptosomes | 2005 |
Effects of systemic administration of iptakalim on extracellular neurotransmitter levels in the striatum of unilateral 6-hydroxydopamine-lesioned rats.
Topics: Adenosine Triphosphate; Animals; Antihypertensive Agents; Apomorphine; Astrocytes; Cells, Cultured; Corpus Striatum; Disease Models, Animal; Dopamine; Dopamine Agonists; Extracellular Fluid; Glutamic Acid; Male; Microdialysis; Neurotransmitter Agents; Parkinsonian Disorders; Pinacidil; Potassium Channels, Inwardly Rectifying; Presynaptic Terminals; Propylamines; Rats; Rats, Sprague-Dawley; Synaptic Transmission | 2006 |
Effect of overexpression of wild-type or mutant parkin on the cellular response induced by toxic insults.
Topics: 1-Methyl-4-phenylpyridinium; Acetylcysteine; Aldehydes; Apoptosis; Cell Death; Cell Line, Tumor; Drug Resistance; Enzyme Inhibitors; Genetic Predisposition to Disease; Glutamic Acid; Guanine; Humans; Hydrogen Peroxide; Mutation; Nerve Degeneration; Neurons; Neurotoxins; Oxidative Stress; Parkinsonian Disorders; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Substantia Nigra; Tyrosine; Ubiquitin-Protein Ligases | 2005 |
DJ-1 mutations and parkinsonism-dementia-amyotrophic lateral sclerosis complex.
Topics: Amyotrophic Lateral Sclerosis; Blotting, Northern; Dementia; DNA Mutational Analysis; Exons; Family Health; Female; Glutamic Acid; Humans; Intracellular Signaling Peptides and Proteins; Male; Mucoproteins; Mutation; Oncogene Proteins; Parkinsonian Disorders; Protein Deglycase DJ-1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2005 |
Mutations in DJ-1 are rare in familial Parkinson disease.
Topics: Aged; Aged, 80 and over; Arginine; Exons; Female; Glutamic Acid; Humans; Intracellular Signaling Peptides and Proteins; Lod Score; Male; Middle Aged; Mutation; Oncogene Proteins; Parkinsonian Disorders; Protein Deglycase DJ-1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2006 |
The influence of group III metabotropic glutamate receptor stimulation by (1S,3R,4S)-1-aminocyclo-pentane-1,3,4-tricarboxylic acid on the parkinsonian-like akinesia and striatal proenkephalin and prodynorphin mRNA expression in rats.
Topics: Animals; Corpus Striatum; Cyclopentanes; Dopamine Antagonists; Dose-Response Relationship, Drug; Enkephalins; Excitatory Amino Acid Agonists; Gene Expression Regulation; Glutamic Acid; Haloperidol; Male; Neural Pathways; Opioid Peptides; Parkinsonian Disorders; Protein Precursors; Rats; Rats, Wistar; Receptors, Metabotropic Glutamate; RNA, Messenger; Substantia Nigra; Synaptic Transmission; Tricarboxylic Acids; Up-Regulation | 2007 |
The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway.
Topics: Animals; Antiparkinson Agents; Benzimidazoles; Bicuculline; Drug Synergism; Drug Therapy, Combination; GABA-A Receptor Antagonists; gamma-Aminobutyric Acid; Glutamic Acid; Injections; Levodopa; Male; Microdialysis; Motor Activity; Neural Pathways; Nociceptin Receptor; Oxidopamine; Parkinsonian Disorders; Perfusion; Piperidines; Postural Balance; Psychomotor Performance; Rats; Rats, Sprague-Dawley; Receptors, Opioid; Sodium Channel Blockers; Stereotaxic Techniques; Substantia Nigra; Tetrodotoxin; Thalamus | 2007 |
Basal ganglia neurotransmitter concentrations in rhesus monkeys following subchronic manganese sulfate inhalation.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Basal Ganglia; Disease Models, Animal; Dopamine; gamma-Aminobutyric Acid; Glutamic Acid; Hydroxyindoleacetic Acid; Inhalation; Macaca mulatta; Manganese Compounds; Neurotransmitter Agents; Norepinephrine; Parkinsonian Disorders; Serotonin; Sulfates | 2007 |
Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo.
Topics: Animals; Benzoates; Corpus Striatum; Dopamine; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Glutamic Acid; Glycine; Male; Molecular Structure; Nerve Degeneration; Neural Pathways; Neuroprotective Agents; Neurotoxins; Oxidopamine; Parkinsonian Disorders; Pyridines; Rats; Rats, Sprague-Dawley; Receptors, Metabotropic Glutamate; Substantia Nigra; Treatment Outcome; Tyrosine 3-Monooxygenase | 2007 |
Metabolic changes detected by proton magnetic resonance spectroscopy in vivo and in vitro in a murin model of Parkinson's disease, the MPTP-intoxicated mouse.
Topics: Animals; Cerebral Cortex; Corpus Striatum; Disease Models, Animal; Dopamine; gamma-Aminobutyric Acid; Glutamic Acid; Glutamine; In Vitro Techniques; Magnetic Resonance Spectroscopy; Male; Mice; Mice, Inbred C57BL; Neural Pathways; Neurochemistry; Neurotransmitter Agents; Parkinsonian Disorders; Protons; Substantia Nigra; Synaptic Transmission; Up-Regulation | 2008 |
Enhanced striatal glutamate release after the administration of rimonabant to 6-hydroxydopamine-lesioned rats.
Topics: Animals; Corpus Striatum; Dose-Response Relationship, Drug; Drug Resistance; Extracellular Fluid; Glutamic Acid; Male; Microdialysis; Neural Inhibition; Oxidopamine; Parkinsonian Disorders; Piperidines; Presynaptic Terminals; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1; Rimonabant; Sympatholytics; Synaptic Transmission; Up-Regulation | 2008 |
Haloperidol reverses the changes in striatal glutamatergic immunolabeling following a 6-OHDA lesion.
Topics: Animals; Apomorphine; Denervation; Dopamine Agonists; Dopamine Antagonists; Glutamic Acid; Haloperidol; Immunohistochemistry; Male; Motor Cortex; Neostriatum; Nerve Degeneration; Neural Pathways; Oxidopamine; Parkinsonian Disorders; Presynaptic Terminals; Rats; Rats, Sprague-Dawley; Time Factors | 2000 |
Increased responsivity of glutamate release from the substantia nigra pars reticulata to striatal NMDA receptor blockade in a model of Parkinson's disease. A dual probe microdialysis study in hemiparkinsonian rats.
Topics: Animals; Corpus Striatum; Denervation; Dizocilpine Maleate; Functional Laterality; Glutamic Acid; Male; Microdialysis; Neurons; Oxidopamine; Parkinsonian Disorders; Perfusion; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Substantia Nigra | 2000 |
Selective vulnerability of pallidal neurons in the early phases of manganese intoxication.
Topics: Animals; Calcium; Calcium Channels; Globus Pallidus; Glutamic Acid; Male; Manganese Poisoning; Nerve Degeneration; Neurons; Parkinsonian Disorders; Patch-Clamp Techniques; Rats; Rats, Wistar | 2000 |
Neuroprotective effects of (+/-)-kavain in the MPTP mouse model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anticonvulsants; Brain; Disease Models, Animal; Dopamine; Dopamine Agonists; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Glutamic Acid; Male; Mice; Mice, Inbred C57BL; Neostriatum; Nerve Degeneration; Neurons; Neuroprotective Agents; Parkinsonian Disorders; Pyrones; Substantia Nigra; Tyrosine 3-Monooxygenase | 2001 |
Blockade of subthalamic glutamatergic activity corrects changes in neuronal metabolism and motor behavior in rats with nigrostriatal lesions.
Topics: Amphetamine; Animals; Dizocilpine Maleate; Energy Metabolism; Excitatory Amino Acid Antagonists; Functional Laterality; Glutamic Acid; Male; Motor Activity; Neostriatum; Neural Pathways; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Substantia Nigra; Subthalamic Nucleus; Succinate Dehydrogenase; Sympatholytics; Synaptic Transmission | 2001 |
Effect of microiontophoretic application of dopamine on subthalamic nucleus neuronal activity in normal rats and in rats with unilateral lesion of the nigrostriatal pathway.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Action Potentials; Animals; Apomorphine; Dopamine; Dopamine Agonists; Drug Interactions; gamma-Aminobutyric Acid; Glutamic Acid; Iontophoresis; Male; Neostriatum; Neural Pathways; Neurons; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Receptors, Dopamine D1; Substantia Nigra; Subthalamic Nucleus; Sympatholytics | 2001 |
Riluzole (2-amino-6-trifluoromethoxy benzothiazole) attenuates MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Astrocytes; Dopamine; Dose-Response Relationship, Drug; Down-Regulation; Drug Interactions; Excitatory Amino Acid Antagonists; Glial Fibrillary Acidic Protein; Glutamic Acid; Homovanillic Acid; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Microtubule-Associated Proteins; Neostriatum; Neurons; Neuroprotective Agents; Parkinsonian Disorders; Riluzole; Substantia Nigra; Tyrosine 3-Monooxygenase | 2001 |
Neuroprotective effect of riluzole in MPTP-treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Dizocilpine Maleate; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Excitatory Amino Acid Antagonists; Glutamic Acid; Homovanillic Acid; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Neostriatum; Neurons; Neuroprotective Agents; Parkinsonian Disorders; Riluzole; Substantia Nigra; Synaptic Transmission; Tyrosine 3-Monooxygenase | 2001 |
Glutamate is not involved in the MPP+-induced dopamine overflow in the striatum of freely moving C57BL/6 mice.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Excitatory Amino Acid Antagonists; Extracellular Space; Glutamic Acid; Herbicides; Male; Mice; Mice, Inbred C57BL; Microdialysis; Neostriatum; Neurons; Parkinsonian Disorders; Receptors, N-Methyl-D-Aspartate; Synaptic Transmission | 2001 |
Prevention of neurotoxin damage of 6-OHDA to dopaminergic nigral neuron by subthalamic nucleus lesions.
Topics: Afferent Pathways; Animals; Biomarkers; Dopamine; Excitatory Amino Acid Agonists; Glutamic Acid; Kainic Acid; Male; Medial Forebrain Bundle; Microinjections; Nerve Degeneration; Nerve Tissue Proteins; Neurons; Neurotoxins; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Substantia Nigra; Subthalamic Nucleus; Tyrosine 3-Monooxygenase; Ventral Tegmental Area | 2000 |
MK801 suppresses the L-DOPA-induced increase of glutamate in striatum of hemi-Parkinson rats.
Topics: Animals; Antiparkinson Agents; Corpus Striatum; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; Glutamic Acid; Levodopa; Male; Microdialysis; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Sympatholytics; Synaptic Transmission | 2002 |
Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzazepines; Corpus Striatum; Dopamine Agonists; Female; Glutamic Acid; Glutamine; Glycine; Macaca fascicularis; Ovariectomy; Parkinsonian Disorders; Receptors, Glutamate; Reference Values | 2002 |